A phase II evaluation of elesclomol sodium and weekly paclitaxel in the treatment of recurrent or persistent platinum-resistant ovarian, fallopian tube or primary peritoneal cancer: An NRG oncology/gynecologic oncology group study.

•Elesclomol increases reactive oxygen species and enhances the efficacy of chemotherapy in preclinical models.•There is no added clinical benefit to paclitaxel when elesclomol is added to treatment of recurrent ovarian cancer.•The combination of paclitaxel and elesclomol is well tolerated.